SuperworthAclaris Therapeutics EPS ACRS
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$0.58
- Latest quarter, Q2 FY26
- −$0.15
- Fiscal year 2025
- −$0.53
Aclaris Therapeutics' earnings per share was −$0.58 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.15.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.53 | n/a |
| FY2024 | −$1.51 | n/a |
| FY2023 | −$1.27 | n/a |
| FY2022 | −$1.33 | n/a |
| FY2021 | −$1.63 | n/a |
| FY2020 | −$1.20 | n/a |
| FY2019 | −$3.91 | n/a |
| FY2018 | −$4.04 | n/a |
| FY2017 | −$2.41 | n/a |
| FY2016 | −$2.26 | n/a |
| FY2015 | −$8.53 | n/a |
| FY2014 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.15 | n/a | −$0.58 | |
| Q1 FY26 | −$0.15 | n/a | −$0.56 | |
| Q4 FY25 | −$0.16 | n/a | −$0.53 | |
| Q3 FY25 | −$0.12 | n/a | −$1.38 | |
| Q2 FY25 | −$0.13 | n/a | −$1.37 | |
| Q1 FY25 | −$0.12 | n/a | −$1.39 | |
| Q4 FY24 | −$1.01 | n/a | −$1.51 | |
| Q3 FY24 | −$0.11 | n/a | −$0.52 | |
| Q2 FY24 | −$0.15 | n/a | −$0.82 | |
| Q1 FY24 | −$0.24 | n/a | −$1.09 | |
| Q4 FY23 | −$0.02 | n/a | −$1.27 | |
| Q3 FY23 | −$0.41 | n/a | −$1.66 |
Against its peers
Companies in Drug Manufacturers - General nearest Aclaris Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ACRSAclaris Therapeutics | −$0.58 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ARVNArvinas | $0.16 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aclaris Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.